Clasificacion Leucemia Mieloide Aguda Oms

From bloodjournal.hematologylibrary.org by guest on September 9, 2011. For personal use only.

2002 100: 2292-2302 Prepublished online June 21, 2002; doi:10.1182/blood-2002-04-1199

The World Health Organization (WHO) classification of the myeloid neoplasms
James W. Vardiman, Nancy Lee Harris and Richard D. Brunning

Updated information and services can be found at:http://bloodjournal.hematologylibrary.org/content/100/7/2292.full.html Articles on similar topics can be found in the following Blood collections Neoplasia (4217 articles) Review Articles (346 articles) Clinical Trials and Observations (3261 articles) Information about reproducing this article in parts or in its entirety may be found online at:http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology,2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.

From bloodjournal.hematologylibrary.org by guest on September 9, 2011. For personal use only.

Review article

The World Health Organization (WHO) classification of the myeloid neoplasms
James W. Vardiman, Nancy Lee Harris, and Richard D. Brunning

A World HealthOrganization (WHO) classification of hematopoietic and lymphoid neoplasms has recently been published. This classification was developed through the collaborative efforts of the Society for Hematopathology, the European Association of Hematopathologists, and more than 100 clinical hematologists and scientists who are internationally recognized

for their expertise in hematopoietic neoplasms. For thelymphoid neoplasms, this classification provides a refinement of the entities described in the Revised European-American Lymphoma (REAL) Classification—a system that is now used worldwide. To date, however, there has been no published explanation or rationale given for the WHO classification of the myeloid

neoplasms. The purpose of this communication is to outline briefly the WHO classification ofmalignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences. (Blood. 2002;100:2292-2302)
© 2002 by The American Society of Hematology

Introduction
Recently, the World Health Organization (WHO), in conjunction with the Society for Hematopathology and the European Association ofHematopathology, published a new classification for hematopoietic and lymphoid neoplasms.1 The concepts that underlie this classification were derived from numerous published clinical and scientific studies and from the experience of more than 100 pathologists, clinicians, and scientists from around the world who collaborated to develop this consensus classification.2 A basic principle of the WHO system is thatthe classification of hematopoietic and lymphoid neoplasms should utilize not only morphologic findings but also all available information, including genetic, immunophenotypic, biologic, and clinical features to define specific disease entities. Essentially, the WHO classification attempts to incorporate those disease characteristics that have proved to have clinical and biologic relevance into auseful, working nomenclature. For the lymphoid neoplasms, the WHO classification provides refinement of the entities defined in the Revised EuropeanAmerican Lymphoma (REAL) Classification—a system that is now widely used by pathologists and clinicians.3 The WHO classification of myeloid neoplasms includes many of the criteria of the French-American-British (FAB) Cooperative Group classifications of acute...